Fiber and Calcium Absorption in Older Men
Modulation of the Gut Microbiome by Dietary Fiber to Improve Calcium Absorption and Bone Health in Older Men
2 other identifiers
interventional
30
1 country
1
Brief Summary
Osteoporotic fractures are a major but underrecognized problem in men. There is growing evidence that low dietary fiber intake is a modifiable risk factor for age-related bone loss in men. Preclinical and human studies in adolescents and postmenopausal women suggest that dietary fiber intake influences bone metabolism by modulating the gut microbiome to augment intestinal calcium absorption, but it is unclear through what molecular mechanism and whether dietary fiber has the same effects in older men. In this crossover intervention study, the investigators will enroll and follow 30 older male Veterans to evaluate the effects of soluble corn fiber on intestinal calcium absorption and explore the contribution of the gut microbiome.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_2
Started Jan 2025
Typical duration for phase_2
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 20, 2024
CompletedFirst Posted
Study publicly available on registry
July 25, 2024
CompletedStudy Start
First participant enrolled
January 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2029
February 17, 2026
February 1, 2026
4 years
June 20, 2024
February 11, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Intestinal fractional calcium absorption
Dual stable calcium isotopic tracer method
At week 4 and week 12 of study participation (at the end of each treatment phase x2)
Secondary Outcomes (4)
Biochemical markers of bone turnover
At week 4 and week 12 of study participation (at the end of each treatment phase x2)
Calciotropic hormones
At week 4 and week 12 of study participation (at the end of each treatment phase x2)
Gut microbial profiling
At week 4 and week 12 of study participation (at the end of each treatment phase x2)
Adherence, tolerability, and acceptability
Throughout study period, an average of 12 weeks
Study Arms (2)
Group 1
EXPERIMENTALSoluble corn fiber 20g/day x 4 weeks, washout period for 4 weeks, and placebo (maltodextrin) x 4 weeks.
Group 2
EXPERIMENTALPlacebo (maltodextrin) 20g/day x 4 weeks, washout period for 4 weeks, and soluble corn fiber x 4 weeks.
Interventions
Soluble corn fiber, also referred to resistant maltodextrin, is a type of dietary fiber made from corn starch. Soluble corn fiber is typically used to thicken processed foods and has been marketed as a prebiotic to improve digestive health.
Eligibility Criteria
You may qualify if:
- Male Veterans 60 years of age
You may not qualify if:
- History of malabsorption
- Hypercalcemia (corrected Ca \> 10.2 mg/dL)
- Vitamin D insufficiency (25OHD \< 30 ng/mL)
- Chronic kidney disease stage 3B or worse (CrCl \< 45 mL/min)
- Severe hypogonadism (AM fasting serum total testosterone \< 150 ng/dL)
- Daily use of proton pump inhibitor
- Use of medication(s) known to affect calcium metabolism
- Use of medications or supplements that could impact gut microbiota in the previous 3 months (antibiotics or commercially available probiotics or prebiotics.
- Presence of a condition or abnormality that in the opinion of the Investigator that would compromise the safety of the patient or the quality of the data.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
San Francisco VA Medical Center, San Francisco, CA
San Francisco, California, 94121-1563, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Karin C Wu, MD
San Francisco VA Medical Center, San Francisco, CA
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Masking Details
- Sachets of soluble corn fiber and placebo will be prepared and assigned randomization numbers by the investigational pharmacist at the San Francisco VA Health Care System. Participants, study staff, and those involved in outcome assessment will be blinded to the group assignment throughout the study.
- Purpose
- OTHER
- Intervention Model
- CROSSOVER
- Sponsor Type
- FED
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 20, 2024
First Posted
July 25, 2024
Study Start
January 1, 2025
Primary Completion (Estimated)
January 1, 2029
Study Completion (Estimated)
January 1, 2029
Last Updated
February 17, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share